Ipamorelin Telehealth

The receipts

Ipamorelin references

Every number on this site traces back to one of these. Click through — that's the point.

How to read this list

Each entry below matches a bracketed number used across the site. Where a study tested a related compound rather than ipamorelin itself — the class-level cardiac study [6] and the CJC-1295 pharmacology, for instance — that's stated plainly in the text where it's cited. Several entries are reviews providing mechanistic context rather than ipamorelin-specific results; those are flagged too. The full citation, PubMed link, and DOI (where one exists) are in the list.

  1. Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. ↗
  2. Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412-1416. ↗
  3. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527-1534. (NCT00672074) ↗
  4. Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999;9(2):106-113. ↗
  5. Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiol Behav. 2024;284:114644. ↗
  6. Stokes AH, Falls JG, Yoon L, Cariello N, Faiola B, Colton HM, Jordan HL, Berridge BR. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist. Int J Toxicol. 2015;34(2):151-161. (Tested compound is GSK894281, a related GHS-R1a agonist, not ipamorelin.) ↗
  7. Zatorski H, et al. Relamorelin and other ghrelin receptor agonists - future options for gastroparesis, functional dyspepsia and proton pump inhibitors-resistant non-erosive reflux disease. J Physiol Pharmacol. 2017;68:797-805. (Review of the ghrelin-agonist class; relevant to ipamorelin via shared GHS-R1a mechanism.) ↗
  8. Van der Ploeg L, et al. Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131. Life Sci. 2014;109:20-29. (Comparative potency study of the ghrelin-mimetic class, which includes ipamorelin-related peptides.) ↗
  9. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110-1116. ↗
  10. Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012;4:149-155. ↗
  11. Sallam HS, Chen JD. The prokinetic face of ghrelin. Int J Pept. 2010;2010:493614. ↗
  12. Hansen TK, et al. Highly potent growth hormone secretagogues: hybrids of NN703 and ipamorelin. Bioorg Med Chem Lett. 2001;11:1915-1918. ↗
  13. Peschke B, et al. The influence of conformational restriction in the C-terminus of growth hormone secretagogues on their potency. Eur J Med Chem. 2002;37:487-501. ↗
  14. Chan CB, et al. Stimulation of growth hormone secretion from seabream pituitary cells in primary culture by growth hormone secretagogues is independent of growth hormone transcription. Comp Biochem Physiol C Toxicol Pharmacol. 2004;139:77-85. ↗
  15. Yeung CM, et al. Seabream ghrelin: cDNA cloning, genomic organization and promoter studies. J Endocrinol. 2006;189:365-379. ↗
  16. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004;25(6):403-406. ↗
  17. Lall S, Tung LY, Ohlsson C, Jansson JO, Dickson SL. Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochem Biophys Res Commun. 2001;280(1):132-138. ↗
  18. Lawrence CB, Snape AC, Baudoin FM, Luckman SM. Acute central ghrelin and GH secretagogues induce feeding and activate brain appetite centers. Endocrinology. 2002;143(1):155-162. ↗